Connect Has A Best-In-Class Anti-IL-13 In Eczema, But Won’t Be Taking On Apogee Yet
The San Diego-based company’s IL-13 inhibitor, rademikibart, has demonstrated best-in-class results in China, but Apogee’s lead in the field looks too strong to challenge.
Scrip - April 1, 2026

Lilly’s Foundayo To Start Shipping Next Week
The US FDA approval of Lilly's orforglipron starts the direct competition with Novo Nordisk's Wegovy Pill.
Scrip - April 1, 2026

Insilico’s CEO On AI, Drug Novelty And Beating China Biotech At R&D
CEO Alex Zhavoronkov talks about the firm’s progress in AI-driven R&D, hitting the right level of drug novelty, partnering with Eli Lilly and its goal of outperforming China’s biopharma engine.
In Vivo - April 1, 2026

International CHC Firms Can Benefit From China’s Tighter E-Commerce Import Rules
China’s tightening cross?border e?commerce rules are reshaping the market in favor of international consumer health brands that can demonstrate genuine overseas provenance, compliance, and real?world market presence, says QIVA Global's Ellie Adams.
HBW Insight - April 1, 2026

Dermapharm Grows With Acquisition Of Wobenzym From Nestlé
Germany's Dermapharm picks up Nestlé subsidiary Mucos Group which markets the enzyme supplement Wobenzym to bolster its consumer health offering.
HBW Insight - April 1, 2026

MedTech Europe Calls For Coordinated Wound Care Policy
A new report from the Wound Care Sector Working Group sounds the alarm: chronic wound care is rapidly becoming a growing burden. The EU must act now to make care coordination, reimbursement and innovation strategic priorities.
Medtech Insight - April 1, 2026

Celltrion Streamlines Keytruda Biosimilar Trial Amid FDA Shift
Celltrion has amended its CT-P51 pembrolizumab Phase III trial as it moves to capitalize on evolving FDA biosimilar guidance, aiming to cut development costs and timelines while aligning with an emerging industry shift toward streamlined clinical requirements.
Generics Bulletin - April 1, 2026

Regulatory Recap: ‘Predictability Is Essential’ For Pharma As Europe-Wide PFAS Ban Moves Forward
Generics Bulletin reviews global regulatory developments across the world.
Generics Bulletin - April 1, 2026

Teva’s Prolia Biosimilar Approved By US FDA As Xolair Rival Filings Accepted In EU And US
Teva marked a three-milestone celebration in its biosimilar portfolio – an approval and dual filing acceptance – as the firm advances its Pivot to Growth strategy.
Generics Bulletin - April 1, 2026

Has Novo Nordisk ‘Killed The Noise’ On Semaglutide Pricing In India?
Novo Nordisk effects price cuts for Ozempic and Wegovy in India taking on the onslaught of semaglutide generics, though the move may pose certain longer-term risks, experts say. The Danish group also has “sufficient" stock of the products but is open to air shipments, if needed.
Scrip - April 1, 2026

BioBytes: AI-Related Deals In Q1 ‘26
AI-led biotech dealmaking in Q1FY26 accelerated across financings, IPOs and pharma alliances, signalling a shift from experimentation to scaled deployment.
In Vivo - April 1, 2026

Factors Driving Change For Medtechs And Biotechs – A Legal View
Goodwin partner Sophie McGrath outlined six key themes for medical device and biotech companies driving innovation or seeking investment in markets now emerging from a relatively subdued fundraising environment in the post-pandemic period.
In Vivo - April 1, 2026

What’s Next? Five Things To Look Out For In April
Generics Bulletin previews the most noteworthy and anticipated events for April 2026.
Generics Bulletin - April 1, 2026